| Theme | Up-to-date Treatment for Inflammatory Bowel Diseases | |
|---|---|---|
| Title | Recently Developed Biologic Therapies for IBD | |
| Publish Date | 2008/05 | |
| Author | Toshifumi Ashida | Third Department of Internal Medicine, Asahikawa Medical College |
| Author | Yutaka Kohgo | Third Department of Internal Medicine, Asahikawa Medical College |
| [ Summary ] | The incidence and prevalence of ulcerative colitis (UC) and Crohn's disease (CD), known to as inflammatory bowel diseases (IBD). have greatly increased in Japan. The precise mechanisms underlying the development of IBD are still not known. However, evidence from clinical trials have proven the efficacy of IBD treatments utilizing newly developed, humanized or human monoclonal antibodies for treatment of pro-inflammatory cytokines. This evidence has been compiled in the US and Europe and a small number of these antibodies are now regarded as new biologics and are already in practical use. Nationwide clinical trials of these drugs have begun or will, soon begin in Japan. The representative data concerning clinical trials of new biologics, and other possible therapeutic modalities will be available in the near future. | |